# CG Oncology Inc. (CGON) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $74.67, market value $6.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). CG Oncology Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1062.7×**. Each dollar of revenue is priced at 1062.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 6.4×**. The shares trade at 6.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.7%** (5-yr avg -4.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -21.4%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -27.6%**. Return on all capital, debt included, is -27.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -28.3%**. Each dollar of assets produces -28.3% of profit.

## Growth
- **Revenue growth (1 yr): 254.7%**. Revenue grew 254.7% over the last year.
- **EPS growth (1 yr): -47.5%**. Earnings per share fell 47.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.1×**. It would take 0.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. CG Oncology Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover CG Oncology Inc.; the consensus is strong_buy, with an average price target of $91.08 (+22% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 141.3%** (YTD 79.8%, 3-mo 39.0%). The shares are up 141.3% over twelve months including dividends.
- **From 52-week high: -7.8%** (132.8% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.14** (volatility 57%). Beta of 1.14 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CGON · Page: https://foliofundamentals.com/stocks/cgon

Not investment advice.